Irland - engelsk - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - human plasma protein >95% immunoglobulins - solution for injection - 160 g/l

Irland - engelsk - HPRA (Health Products Regulatory Authority)

biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin varicella-zoster - solution for injection

Irland - engelsk - HPRA (Health Products Regulatory Authority)

biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin varicella-zoster - solution for injection - 5g/1250iu/50 ml %v/v

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - hepatitis b immunoglobulin, human 160 mg/ml ((>= 98% )as human plasma proteins (exnz)) - solution for injection - 100 iu - active: hepatitis b immunoglobulin, human 160 mg/ml ((>= 98% )as human plasma proteins (exnz)) excipient: glycine water for injection - hepatitis b immunoglobulin-vf is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (< 10 iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin-vf is also indicated for prophylaxis in infants born to hbsag-positive mothers.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - hepatitis b immunoglobulin, human 160 mg/ml (( >= 98%) as human plasma proteins (ex nz)) - solution for injection - 400 iu - active: hepatitis b immunoglobulin, human 160 mg/ml (( >= 98%) as human plasma proteins (ex nz)) excipient: glycine water for injection - hepatitis b immunoglobulin-vf is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (< 10 iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin-vf is also indicated for prophylaxis in infants born to hbsag-positive mothers.

Irland - engelsk - HPRA (Health Products Regulatory Authority)

biotest pharma gmbh - human plasma protein >96% immunoglobulins - solution for infusion - 50 gram(s)/litre - immunoglobulins, normal human; immunoglobulins, normal human, for intravascular adm.

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

bio products laboratory ltd - varicella-zoster immunoglobulin human - solution for injection - 250mg

Irland - engelsk - HPRA (Health Products Regulatory Authority)

octapharma limited - human plasma protein - solution for infusion - %v/v - blood substitutes and plasma protein fractions

Irland - engelsk - HPRA (Health Products Regulatory Authority)

octapharma (ip) sprl - human plasma protein - solution for infusion - . percent volume/volume - blood substitutes and plasma protein fractions

Irland - engelsk - HPRA (Health Products Regulatory Authority)

octapharma (ip) sprl - human plasma protein - powder and solvent for solution for infusion - blood substitutes and plasma protein fractions